This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below.

Trial Design: FIDELIO-DKD:

Phase 3, randomised, double-blind, placebo-controlled, multicentre, clinical trial conducted in 48 countries

Adapted from Bakris
- At baseline:
- 87.5% of patients had UACR levels ≥300 mg/g at baseline
- 99.9% of patients received a tolerated dose of an ACEi or ARB
- 97.4% of patients used glucose-lowering medication
- The primary renal outcome was the time to the first occurrence of the composite endpoint of:
- onset of kidney failure†, or
- a sustained decrease of eGFR ≥ 40% from baseline over at least 4 weeks, or
- death due to renal causes.
- The secondary cardiovascular outcome was the time to first occurrence of the composite endpoint of:
- CV death, or
- non-fatal MI, or
- non-fatal stroke, or
- hospitalisation for HF
*Includes an ACEi or ARB at the maximum tolerated dose.
†Defined as end-stage kidney disease (initiation of dialysis for ≥90 days or kidney transplantation) or an eGFR <15 mL/min/1.73 m2 over ≥4 weeks.
Trial Design
FIDELIO-DKD: Selected inclusion and exclusion criteria

Adapted from Bakris
Trial Design
Patient characteristics were well balanced between groups in the FIDELIO-DKD trial
Key Baseline Characteristics | Kerendia (n=2833) | Placebo (n=2841) |
---|---|---|
Race (%) | ||
White | 62.7 | 63.9 |
Black | 4.9 | 4.4 |
Asian | 25.3 | 25.4 |
Other | 7.0 | 6.3 |
Mean age (years) | 65.4 | 65.7 |
Male (%) | 68.9 | 71.5 |
Mean eGFR (mL/min/1.73 m²) | 44.4 | 44.3 |
eGFR distribution (mL/min/1.73 m², %) | ||
| 54.4 | 55.4 |
45 to >60 | 34.3 | 32.7 |
≥60 | 11.2 | 11.9 |
Median UACR (mg/g) | 833 | 867 |
Mean HbA1c (%) | 7.7 | 7.7 |
History of cardiovascular disease (%) | 46.0 | 45.8 |
Trial Design
Patients in both groups were well managed on background therapy for CKD and T2D, respectively
The trial run-in period allowed for background medical therapies to be adjusted, including adjustment of ACEi or ARB therapy to a maximum labelled dose that did not cause unacceptable side effects.
Baseline medications (a) | Kerendia (n=2833) | Placebo (n=2841) |
---|---|---|
ACEi† | 33.5% | 34.9% |
ARB† | 66.3% | 65.0% |
Alpha-blocking agent | 24.5% | 25.2% |
Beta-blocker | 51.6% | 53.0% |
Calcium antagonist | 62.6% | 63.8% |
Diuretics | 55.7% | 57.6% |
Loop diuretic | 27.7% | 29.3% |
Thiazide diuretic | 24.7% | 23.1% |
Statin | 74.3% | 74.3% |
Platelet aggregation inhibitor (b) | 57.6% | 56.1% |
Potassium-lowering agent (c) | 2.5% | 2.3% |
Glucose-lowering therapies | 97.0% | 97.7% |
Insulin | 65.1% | 63.1% |
Metformin | 44.2% | 43.6% |
Sulphonylurea | 23.1% | 23.7% |
DPP-4 inhibitors | 27.0% | 26.7% |
Alpha-glucosidase inhibitor | 5.8% | 5.7% |
GLP-1 receptor agonists | 6.7% | 7.2% |
SGLT2 inhibitors | 4.4% | 4.8% |
(a)At baseline, 14 patients were not treated with an ACE inhibitor or ARB;
7 patients were treated with both an ACE inhibitor and ARB
(b)Excluding heparins
(c)These agents included sodium polystyrene sulfonate, calcium polystyrene sulfonate, and potassium-binding agents
Trial Design
Planned patient population by KDIGO stratification

- Bluelow risk (if no other markers of kidney disease, no CKD)
- Yellowmoderately increased risk
- Orangehigh risk
- Redvery high risk
Adapted from KDIGO Diabetes Work Group
ACEi=angiotensin-converting enzyme inhibitor; ARB=angiotensin receptor blocker; CKD=chronic kidney disease; CV=cardiovascular; DKD=diabetic kidney disease; DPP-4=dipeptidyl peptidase-4; eGFR=estimated glomerular filtration rate; GFR=glomerular filtration rate; GLP-1=glucagon-like peptide-1; HbA1c=glycated haemoglobin; HF=heart failure; KDIGO=Kidney Disease: Improving Global Outcomes; MI=myocardial infarction; MOD=mechanism of disease; MOA=mechanism of action; OD=once daily; RAAS=renin-angiotensin-aldosterone system; SGLT2=sodium-glucose cotransporter 2; T2D=type 2 diabetes: UACR=urine albumin-to-creatinine ratio.
PP-KER-GB-0471 | March 2024
- Referencesexpand_more
- 1GB Kerendia SmPC, NI Kerendia SmPC
- 2Bakris GL, et al; FIDELIO-DKD Investigators. N Engl J Med. 2020;383(23):2219-2229.